Progenics Pharmaceuticals (PGNX) - 21 Year Stock Split History

Historical stock splits for Progenics Pharmaceuticals since 1997. Prices shown are actual historical values and are not adjusted for either splits or dividends. Please see the "Historical Prices" tab for adjusted price values.
Progenics Pharmaceuticals Annual Stock Splits
Progenics Pharmaceuticals Quarterly Stock Splits
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.592B $0.012B
Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics' first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic in a two-cohort phase 2 clinical trial and a small molecule imaging agent that has completed patient dosing in a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra(TM), an ultra-orphan radiotherapy candidate also in a phase 2 study under an SPA. Progenics' first commercial product, Relistor(R) (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $62.614B 10.74
Teva Pharmaceutical Industries (TEVA) Israel $22.493B 6.28
Mylan (MYL) United Kingdom $19.860B 8.45
Bausch Health Cos (BHC) Canada $7.504B 5.60
Dr Reddy's Laboratories (RDY) India $5.393B 24.09
Mallinckrodt Public Limited Company (MNK) United Kingdom $2.683B 4.56
Akorn (AKRX) United States $2.382B 11.80
Supernus Pharmaceuticals (SUPN) United States $2.230B 23.85
Assembly Biosciences (ASMB) United States $0.950B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.818B 117.87
CymaBay Therapeutics (CBAY) United States $0.735B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.637B 0.00
Homology Medicines (FIXX) United States $0.630B 0.00
Voyager Therapeutics (VYGR) United States $0.587B 0.00
Corium (CORI) United States $0.336B 0.00
Teligent (TLGT) United States $0.232B 0.00
Sol-Gel Technologies (SLGL) Israel $0.120B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.114B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.077B 0.00
Versartis (VSAR) United States $0.063B 0.00
Aevi Genomic Medicine (GNMX) United States $0.057B 0.00
Evoke Pharma (EVOK) United States $0.041B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.023B 0.00
Acasti Pharma (ACST) Canada $0.017B 0.00
China Pharma Holdings (CPHI) China $0.011B 0.00
Agile Therapeutics (AGRX) United States $0.009B 0.00